EQS — News: Opella: New study demonstrates successful cough treatment extends beyond symptom relief

EQS-News: Opella / Key word(s): Miscellaneous Opella: New study demonstrates successful cough treatment extends beyond symptom relief 15.10.2026 / 01:05 CET/CEST The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════ PARIS, Oct. 15, 2026 // — A new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that the success of a cough treatment should be measured by its impact on a patient's overall well-being, alongside traditional symptomatic relief. 1 Opella With most consumers^1 making treatment decisions in the pharmacy, the pharmacist's recommendation plays a pivotal role in helping patients return to their normal routines and make the moment theirs again. Key Findings: • Fast Relief from the First Dose: Patients reported fast relief from the very first dose of treatment^2, with data showing improvements in daily functioning from the first day of treatment, allowing them to rapidly start regaining control over their day. • Restored Social Engagement